Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab.

已完结 10 由 zj 发布于 2025/5/21 23:56:43

DOI:10.1136/gutjnl-2024-334026
作者：Yuta Myojin,?Sepideh Babaei,?Rajiv Trehan,?Christoph Hoffman,?Noemi Kedei,?Benjamin Ruf,?Mohamed-Reda Benmebarek,?Kylynda C Bauer,?Patrick Huang,?Chi Ma,?Cecilia Monge,?Changqing Xie,?Donna Hrones,?Au
文献类型：期刊论文
补充材料：只需要正文

BMJ

Abstract：Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC.

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Royal Society of Chemistry (RSC)Fluoride-assisted crystallization regulation enables efficient and stable wide-bandgap perovskite photovoltaic?